文献速递慢阻肺呼吸道感染

基于个体化治疗效应模型识别慢阻肺阿奇霉素应答者

Identifying azithromycin responders with an individual treatment effect model in COPD.
PubMed 文献 · Thorax · 2025-11-14

本研究利用MACRO试验1025例患者数据,采用因果森林模型估计阿奇霉素对年急性加重率的个体化治疗效应,并在COLUMBUS试验83例患者中独立验证。结果显示,预测获益最大的三分位患者年急性加重率显著且大幅下降,而其余三分之二患者未见显著疗效。五个易获取参数可识别治疗效应异质性,提示小部分应答者驱动了既往试验的平均获益。

要点

  • 基于五个易获取参数可识别阿奇霉素预防慢阻肺急性加重的应答者。
  • 预测获益最大的三分位患者年急性加重率下降显著大于全队列平均效应。
  • 其余三分之二患者未观察到显著治疗效应,提示需避免不必要暴露。

核心结论

  • 基于五个易获取参数预测个体化治疗效应,可识别慢阻肺阿奇霉素维持治疗中的小部分应答者,其驱动了既往试验报告的平均急性加重减少。

研究设计与样本

  • 利用MACRO试验1025例患者数据,采用因果森林因果机器学习模型评估阿奇霉素对年急性加重率的个体化治疗效应。
  • 使用COLUMBUS试验83例患者数据独立验证 findings。

主要发现

  • MACRO中预测个体化治疗效应最佳三分位患者年急性加重率降低-0.50(率比0.70,p=0.01),COLUMBUS中为-2.28(率比0.43,p<0.001)。
  • 全队列平均治疗效应在MACRO为-0.35(率比0.83,p=0.01),COLUMBUS为-1.28(率比0.58,p=0.001)。
  • 其余三分之二患者未观察到显著治疗效应。
  • 个体化治疗效应的主要决定因素包括呼吸道症状、白细胞计数、血红蛋白、C反应蛋白和用力肺活量,吸烟状态不是显著预测因素。

临床怎么用

  • 可利用呼吸道症状、白细胞计数、血红蛋白、C反应蛋白和用力肺活量五个易获取参数评估慢阻肺患者阿奇霉素预防治疗的个体化获益可能性。
  • 对预测获益低的患者可考虑避免长期阿奇霉素暴露以减少不必要用药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Long-term azithromycin treatment effectively prevents acute exacerbations of chronic obstructive pulmonary disease (COPD). However, patients would benefit from better identification of responders and non-responders to minimise unnecessary exposure. We aimed to assess treatment effect heterogeneity and estimate individual treatment effects (ITEs) to distinguish patients most likely to benefit from prophylactic treatment. METHODS: We used data from 1025 patients of the MACRO trial to assess the ITE of azithromycin on annual exacerbation rate. A Causal Forest was used as a causal machine learning model. We independently validated our findings using data from 83 patients of the COLUMBUS trial. RESULTS: The tertile of patients with the best predicted ITE within MACRO and within the COLUMBUS independent validation cohort showed significant and substantially greater reductions in annual exacerbation rates (in MACRO -0.50, rate ratio 0.70, p=0.01, in COLUMBUS: -2.28, rate ratio 0.43, p<0.001) compared with the average treatment effect across the entire cohort (MACRO -0.35, rate ratio 0.83, p=0.01 and COLUMBUS -1.28, rate ratio 0.58, p=0.001). Conversely, no significant treatment effect was observed in the remaining two-thirds of patients. Primary determinants of ITE included respiratory symptoms, white blood cell count, haemoglobin, C-reactive protein and forced vital capacity. Smoking status did not emerge as a significant predictor. CONCLUSION: Based on five easily obtainable parameters to predict ITE, we identified treatment effect heterogeneity in COPD subjects treated with azithromycin maintenance therapy and found a small subgroup of responders driving the average reduction in exacerbations reported in previous trials.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Verstraete, Gyselinck, Huts, et al. Identifying azithromycin responders with an individual treatment effect model in COPD. Thorax. 2025. PMID: 40610208. doi:10.1136/thorax-2025-223095

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。